Search Results for: dndn

DNDN: Studies are impressive – AGAIN!

It is one day after the House Energy and Commerce Committee sent a declination letter to the four Congressmen that had been requesting a further review of the questionable FDA ruling for Dendreon’s (DNDN) Provenge, the company’s groundbreaking Prostate cancer drug. Now, a news release shows another beneficial study result...

Read More

DNDN – More Info and More Confusion on Provenge

The saga continues with DNDN. The stock is moving a bit higher. There are many people’s lives that may now be in further disarray as the long-awaited and deeply hoped-for FDA approval of the prostrate cancer treatment Provenge has been delayed. There is a rather large commotion concerning several inconsistencies...

Read More

MarketMash: April Fool’s Week

A week full of fun and adventure in the stock market. Fun stories, rants and other observations that you may find of interest.

David Gaffen over at the WSJ was somewhat blah about Fitch cutting the rating on MBIA (MBI). DAVE: It could be worse, they could have raised them to...

Read More

TDI Episode 49: Pharma Huckman’s Market

Guest: Mike Huckman, CNBC Pharmaceutical Reporter brings great deal of timely information regarding the Pharma and Biotech sectors. We discuss Merck (MRK), Amgen (AMGN), Genentech (DNA), Dendreon (DNDN), Pfizer (PFE) and others.

Mike’s writes a terrific blog and appears daily on CNBC.

Andrew discusses the current markets and provides a few...

Read More

Dendreon’s News – Good Spin, No Spunk

Dendreon (DNDN) is one again in the news. At first, it appears that there is a faster track that the FDA is allowing when it comes to the trials for Provenge. If you read the news item it is really nothing significant, yet it is may be a hint...

Read More

  • 1
  • 2

false